President Bio-den? Executive Order Highlights Value Of Biotech – But Doesn’t Change Pricing Message
Executive Summary
The White House is playing up a new initiative to support ‘biotechnology and biomanufacturing.’ The focus on innovation is always a welcome theme – but it does not signal any change in the emphasis on cutting drug pricing in the Biden Administration.
You may also be interested in...
US Pricing Reform Puts Cancer Drug Innovation At Risk, Drug Leaders Warn
Merck & Co. CEO Rob Davis, Regeneron president George Yancopoulos, Pfizer R&D president Mikael Dolsten and others weighed in at the Galien Forum on the potential impact of the US Inflation Reduction Act on innovation.
US-China Decoupling Gets On Biotech's Nerves
The Biden Administration’s latest Executive Order is aimed at shoring up investment in the US and securing supply chains for pharma and biotech products and is already impacting China's CDMO sector, but the long-term impact may be more nuanced, experts predict.
Don’t Look Up? Congress Can’t Ignore Risk To Small Molecule Drugs In Pricing Bill, Investors Warn
A budget-neutral fix that would extend the time before small molecule drugs are subject negotiations but increase the minimum discounts for the products is floated as the pricing legislation moves toward a Senate floor vote.